Herpes Simplex Virus Types 1 and 2

Herpes Simplex Virus (HSV) is not merely a common cause of painful sores; it is a master of persistence, a model for viral latency, and a significant cause of severe neurological disease. Understanding the distinctions between HSV-1 and HSV-2 is crucial for clinical diagnosis, patient counseling, and mastering foundational microbiology and neurology concepts for exams like the MCAT.

Viral Structure and Classification

Herpes Simplex Virus is an enveloped, double-stranded DNA virus belonging to the Herpesviridae family. Its structure is a classic study in viral efficiency. At its core lies the linear dsDNA genome, which is packaged within an icosahedral capsid. This capsid is surrounded by an amorphous protein layer called the tegument, which contains viral enzymes and proteins essential for initiating infection. The entire structure is encased in a host-derived envelope studded with viral glycoproteins, most notably glycoprotein B and D, which are critical for attachment and entry into host cells.

This structural complexity facilitates a sophisticated life cycle. After the envelope fuses with the host cell membrane, the capsid is transported to the nucleus where the viral DNA is released. Viral DNA replication and transcription occur in the nucleus, utilizing a combination of viral and host machinery. Newly assembled capsids then bud through the inner nuclear membrane, acquiring their envelope, and are ultimately released from the cell. For the MCAT, focus on the key takeaways: dsDNA genome, nuclear replication, and the presence of an envelope—which makes the virus susceptible to drying and disinfectants like soap.

Epidemiology and Primary Clinical Presentation

The two types, HSV-1 and HSV-2, are distinguished antigenically and by their typical, though not exclusive, clinical patterns. HSV-1 is most commonly associated with oral herpes, causing cold sores or fever blisters on the lips, mouth, and face. It is often acquired in childhood through non-sexual contact with infected saliva. In contrast, HSV-2 is predominantly a sexually transmitted infection and is the primary cause of genital herpes, characterized by painful vesicular lesions on the genitalia or rectum.

It is vital to move beyond this simple dichotomy for clinical and exam accuracy. Due to changing sexual practices, HSV-1 is now responsible for an increasing proportion of first-episode genital herpes infections. Conversely, HSV-2 can cause oral lesions. The primary infection for either type is often the most severe, featuring systemic symptoms like fever, malaise, and tender lymphadenopathy (swollen lymph nodes) in addition to the classic grouped vesicles on an erythematous (red) base. These vesicles rupture, forming shallow, painful ulcers that eventually crust over and heal without scarring.

Pathophysiology: Latency and Reactivation

The defining feature of herpesviruses is their ability to establish latency, a state of dormant, lifelong infection with no viral replication. After primary infection at a mucosal surface or abraded skin, the virus travels retrograde (up the nerve axon) via sensory neurons to the cell bodies in the sensory ganglia. Here, the viral genome persists as a closed circular episome in the neuronal nucleus.

The site of latency is a critical differentiator for the two types and a high-yield fact. HSV-1 establishes latency primarily in the trigeminal ganglion, which services sensation to the face and mouth. HSV-2 establishes latency in the sacral ganglia (specifically the dorsal root ganglia S2-S5), which service the genital region. Think of the ganglia as a dormant hard drive where the viral program is stored but not running.

Periodically, due to stressors like illness, immunosuppression, UV light (for oral herpes), or even menstruation, the virus reactivates. It travels anterograde (back down the nerve) to the original site of infection or nearby dermatomes, leading to recurrent vesicular lesions. These recurrences are typically less severe than the primary episode. Importantly, viral shedding can occur in the absence of visible lesions (asymptomatic shedding), which is a major driver of transmission.

Treatment and the Mechanism of Acyclovir

Effective management hinges on antiviral nucleoside analogues, with acyclovir being the prototype. Its mechanism is a masterpiece of selective toxicity and a favorite exam topic. Acyclovir is a guanosine analogue. For it to become active, it must first be phosphorylated. This initial phosphorylation is performed almost exclusively by a viral thymidine kinase (TK), not host kinases. This is the first level of selectivity.

Once converted to acyclovir monophosphate by viral TK, host cellular kinases add two more phosphates to form acyclovir triphosphate. This active form then competes with deoxyguanosine triphosphate (dGTP) for incorporation into the growing viral DNA chain by viral DNA polymerase. When incorporated, it acts as a chain terminator because it lacks the 3'-OH group needed to form the next phosphodiester bond. Viral DNA polymerase has a much higher affinity for acyclovir triphosphate than host DNA polymerase, providing the second level of selectivity. This dual selectivity makes acyclovir highly effective and relatively non-toxic to host cells. It is used to treat active infections and, at lower doses, to suppress frequent recurrences.

HSV-1 Encephalitis: A Neurological Emergency

Beyond mucocutaneous lesions, HSV-1 holds a grave distinction: it is the most common cause of sporadic, fatal viral encephalitis in adults. This condition is a true neurological emergency. HSV encephalitis typically involves the temporal lobes and limbic system, reflecting the virus's path of reactivation from the trigeminal ganglion. For the MCAT, the association of HSV-1 with temporal lobe encephalitis is an absolute must-know.

Patients present with acute-onset fever, headache, personality changes, bizarre behavior, and focal neurological deficits like aphasia or seizures. Diagnosis is confirmed via PCR detection of HSV DNA in cerebrospinal fluid (CSF). Crucially, CSF analysis may show a lymphocytic pleocytosis and elevated protein, but the PCR is the gold standard. Imaging (MRI) often reveals edema and hemorrhage in the temporal lobes. Treatment involves high-dose intravenous acyclovir. Delay in treatment leads to significant mortality and morbidity, making rapid recognition and empirical therapy paramount.

Common Pitfalls

1. Assuming Strict Anatomical Separation of HSV-1 and HSV-2: A classic trap is believing HSV-1 only causes oral lesions and HSV-2 only causes genital lesions. You must understand that either virus can infect either site, and the epidemiology is shifting. On exams, always interpret the clinical scenario in light of patient history, not just the lesion location.
2. Confusing Latency with Inactivity: Latency does not mean the virus is harmless. Asymptomatic viral shedding from mucosal surfaces occurs during latency and is a key mode of transmission. Furthermore, the latent virus can reactivate to cause disease. The virus is never truly "cleared" by the immune system.
3. Misunderstanding Acyclovir's Selectivity: The common mistake is to state acyclovir "inhibits viral DNA polymerase." While true, this misses the crucial first step: activation by viral thymidine kinase. The drug's safety and efficacy rely on this two-step selective mechanism. Be prepared to explain the entire pathway.
4. Overlooking or Misdiagnosing HSV Encephalitis: In a clinical vignette, presenting symptoms like personality change, fever, and seizures should immediately raise the red flag for HSV encephalitis, especially if temporal lobe signs are mentioned. Do not dismiss it as a psychiatric illness. Remember, PCR of CSF, not serum antibody titers, is diagnostic for active CNS infection.

Summary

• Herpes Simplex Virus (HSV) is an enveloped double-stranded DNA virus with two primary types: HSV-1, classically causing oral herpes, and HSV-2, predominantly causing genital herpes, though cross-infection is common.
• The hallmark of HSV pathogenesis is latency in sensory ganglia: HSV-1 in the trigeminal ganglion and HSV-2 in the sacral ganglia. Periodic reactivation leads to recurrent symptomatic lesions or asymptomatic viral shedding.
• Acyclovir exerts its selective antiviral effect by first being activated by viral thymidine kinase and then inhibiting viral DNA polymerase, acting as a DNA chain terminator.
• HSV-1 is the leading cause of sporadic viral encephalitis in adults, characteristically targeting the temporal lobes. This is a medical emergency diagnosed by CSF PCR and treated with high-dose IV acyclovir.
• For exam success, focus on the mechanisms (latency, drug action), clinical correlations (oral vs. genital, encephalitis), and avoid the common pitfalls of anatomical stereotyping and oversimplifying drug mechanisms.